Annual General Meeting in ALK-Abelló A/S held on 13 March 2025

Last updated: 2025.03.13

ACARIZAX® approved in Canada for treatment of young children

Last updated: 2025.03.07

Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff

Last updated: 2025.03.04

FDA approves ODACTRA® for the treatment of house dust mite allergy in young children

Last updated: 2025.02.27

Invitation to the presentation of ALK’s annual report 2024 on Wednesday, 19 February 2025

Last updated: 2025.02.12

ALK’s house dust mite tablet (ACARIZAX®) now recommended by NICE for use in the UK health system

Last updated: 2025.01.30

ALK – Financial calendar for the 2025 financial year

Last updated: 2024.12.20

Positive results advance peanut tablet to phase II development

Last updated: 2024.12.18

ALK Christmas Party

Last updated: 2024.12.17

ALK Halloween 2024

Last updated: 2024.10.31